General Motors Company (GM) Stock Price Today
Aura AI Summary
Key Stats
- $69.73BMARKET_CAP
- -VOLUME
- Consumer CyclicalSECTOR
- $86.38FIFTY_TWO_WEEK_HIGH
- $48.89FIFTY_TWO_WEEK_LOW
- -TYPICAL_HOLD_TIME
- $173.07BENTERPRISE_VALUE
- 0.95%DIVIDEND_YIELD
- -TRADING_ACTIVITY
Track General Motors Company (GM) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, General Motors Company has traded between a low of $48.89 and a high of $86.38, highlighting its annual price range. Buy and sell General Motors Company shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Most Recent News
Global infant heart monitor market to reach $7.93B by 2035 with 10.85% CAGR, driven by tech advances and home care demand
The global infant heart monitor market, valued at $2.83 billion in 2025, is projected to grow to $7.93 billion by 2035 at a CAGR of 10.85%. Growth is fueled by advances in wearable and wireless monitoring technologies, increased adoption of home care...

Halper Sadeh LLC probes fairness of major company sales for shareholders' benefit.
Halper Sadeh LLC is investigating whether shareholders of Arcosa, Bio-Techne, Iridium Communications, and LCI Industries are receiving fair deals in their companies' recent sales. The law firm suspects insiders may gain financial benefits not availab...

Europe approves TEPKINLY combo for relapsed follicular lymphoma, offering a chemo-free treatment option.
The European Commission has approved TEPKINLY (epcoritamab) combined with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma in adults. This marks the first bispecific antibody-based therapy authorized in Europe for se...
